ADVAIR Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Advair, and when can generic versions of Advair launch?
Advair is a drug marketed by Glaxo Grp Ltd and is included in two NDAs.
The generic ingredient in ADVAIR is fluticasone propionate; salmeterol xinafoate. There are twenty-nine drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the fluticasone propionate; salmeterol xinafoate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Advair
A generic version of ADVAIR was approved as fluticasone propionate; salmeterol xinafoate by HIKMA on December 17th, 2020.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for ADVAIR?
- What are the global sales for ADVAIR?
- What is Average Wholesale Price for ADVAIR?
Summary for ADVAIR
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 2 |
| Drug Prices: | Drug price information for ADVAIR |
| Drug Sales Revenues: | Drug sales revenues for ADVAIR |
| What excipients (inactive ingredients) are in ADVAIR? | ADVAIR excipients list |
| DailyMed Link: | ADVAIR at DailyMed |
